Lv71
3420 积分 2022-08-15 加入
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
6小时前
已关闭
Expert opinion on managing adverse reactions associated with acalabrutinib therapy: A Delphi consensus from France
1天前
待确认
Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months
2天前
已关闭
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
2天前
已完结
Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation
2天前
已完结
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
3天前
已完结
Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When
4天前
已关闭
Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study
9天前
已完结
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies
13天前
已关闭
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies
13天前
已关闭
皖公网安备34019202002308
